Asco Releases Updated Clinical Practice Guideline On The Use Of Antiemetics For Cancer Patients
The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation.
Alexandria, VA - The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation. The guideline update, which also reviews the likelihood of various cancer treatments to cause vomiting, will be published in the June 20, 2006, print issue of the Journal of Clinical Oncology.
Since the release of an evidence-based clinical practice guideline on the use of antiemetics in 1999, new research is available on treatments to prevent nausea and vomiting in cancer patients. In addition, new cancer treatments such as trastuzumab, which treats advanced breast cancer, and erlotinib, which treats metastatic pancreatic and non-small cell lung cancer, are less likely to cause nausea and vomiting.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
